Sentrx™ Animal Care, Inc. Announces Manufacturing Facility Expansion to Accommodate Accelerated Growth
1.7.2021 17:03:00 EEST | Business Wire | Press release
On May 20th, 2021 Sentrx Animal Care held a ribbon cutting ceremony to celebrate the completion and opening of its brand new 22,000 square foot manufacturing facility in Salt Lake City, Utah. The expansion into this larger new facility represents a major milestone for the Salt Lake City based company. The design of the new space includes 1,689 square feet of ISO 7 clean room and 1,420 square feet of wet lab, accommodating the manufacturing capacity and capabilities required to support Sentrx’s accelerating growth in the United States, and in new markets abroad, as well as expanding R&D initiatives that build upon Sentrx’s patented BioHAnce platform technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005040/en/
Sentrx ribbon-cutting ceremony for new facility in Salt Lake City, Utah (Photo: Business Wire)
Working with Engage Contracting, Inc. as the general contractor on the project, Sentrx broke ground in November 2020. By the end of April 2021, manufacturing was online and fully validated in the new space. Sentrx also completed ISO audits in April and maintains ISO 13485 certification in this new facility.
“The completion of this project marks an exciting milestone for Sentrx,” said Brian Segebrecht, Chief Executive Officer. “Sentrx runs a vertically integrated manufacturing operation, procuring only raw materials and components from third parties. This allows for complete control over quality and the highly proprietary processes we have developed for manufacturing our three in-market formulations at large commercial scale. Our expansion to this new facility ensures our ability to remain a vertically integrated manufacturing operation with the capacity required to support the accelerating growth of our in-market products, as well as the robust pipeline of future innovation we have planned for the BioHAnce platform.”
Sentrx was founded on exclusive, worldwide rights to BioHAnce Technology, a patented and proprietary technology that uses advanced bioengineering to create a molecular matrix of crosslinked hyaluronic acid (HA) that can be specifically modified for each formulation and particular tissue environment, including ocular and skin surfaces. It produces a cellular scaffolding with unique physical and chemical properties that enhances hydration, accelerates the body’s own healing processes, and extends duration in tissue. Sentrx currently sells three product formulations containing the BioHAnce Technology. In the US these products are marketed under the brand names Ocunovis™, Oculenis™ and Episanis™.
Related Information
Sentrx™ Animal Care, Inc. website: www.sentrxanimalcare.com
Online press releases: www.sentrxanimalcare.com/news
Sign up for the Sentrx veterinarian newsletter here
Product information:
Ocunovis™ BioHAnce™ Gel Eye Drops
Oculenis™ BioHAnce™ Ocular Repair Gel
Episanis™ BioHAnce™ Skin and Wound Gel
About Sentrx™ Animal Care, Inc.
Sentrx is a Salt Lake City-based animal health company that develops and manufactures veterinary wound care and ophthalmic products for companion animals. Sentrx transforms complex biotechnologies into easy-to-use care solutions that promote the long-term well-being of animals.
Sentrx was founded on technology from the University of Utah and collaborates with a variety of veterinary academic institutions and practicing veterinarians. The company’s unique combination of medicinal chemistry, bioengineering, and product manufacturing capabilities allow it to deliver cutting-edge animal care solutions. To learn more, visit our website at sentrxanimalcare.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005040/en/
Contact information
Mason Williams, Chief Commercial Officer
Sentrx™ Animal Care, Inc.
(801) 583-2050
mwilliams@sentrxanimalcare.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves Crysvita ® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union21.7.2026 10:00:00 EEST | Press release
Kyowa Kirin EMEA, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151), today announced that the European Commission (EC) has approved an expansion of the indication for Crysvita® (burosumab) for the treatment of X-linked hypophosphataemia (XLH), to include infants from 1 month to 1 year of age across the European Union and European Economic Area. The approval represents an important step forward for infants living with XLH, a rare, progressive genetic disease that can affect skeletal development from an early age. Earlier diagnosis and treatment are considered important in XLH given the potential impact of the disease on skeletal development during infancy and childhood. XLH is a rare, progressive, lifelong genetic disease characterised by phosphate wasting that can impair bone mineralisation from an early age, leading to skeletal deformities, impaired growth and other serious complications. Clinical manifestations of XLH can emerge during infancy and early childhood, with pr
CapVest Completes Acquisition of TSG21.7.2026 10:00:00 EEST | Press release
CapVest Partners LLP (“CapVest”), a leading New York and London based investment firm, today announces that it has completed its acquisition of a majority stake in TSG Solutions (“TSG”), a European leader in technical services for critical energy infrastructure, following receipt of all necessary approvals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721628079/en/ TSG Headquartered in Paris, France, TSG operates across 30 countries with over 7,000 employees and annual revenues of more than €1.4 billion. The company designs, builds and maintains critical energy infrastructure across Power (HV, MV & LV electrical), Charge, Solar, Battery Energy Storage Systems (BESS), Biofuels and Gas & Biogas. TSG’s multi-energy capabilities, deep technical expertise and extensive geographical coverage underpin longstanding relationships with a diverse base of leading energy infrastructure operators, and position the company to capture
Ant International Raises approx. US$1.2 billion in Series A Equity Financing to Boost Cross-border Payments, Agentic Commerce Solutions for Global Businesses21.7.2026 06:00:00 EEST | Press release
Ant International, a leading global digital payment, digitisation and financial technology provider, today announced the successful closing of its Series A equity financing of approximately US$1.2 billion. Existing investors including Ant Group and Alibaba Group participated in this round, as well as other renowned international investment institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260720424592/en/ Ant International today announced the successful closing of its Series A equity financing of approximately US$1.2 billion. The proceeds will be used to accelerate Ant International’s global expansion and innovation in merchant payment, account management and other inclusive financial services for SMEs and enterprises across the world. Ant International began independent operation in 2024. With main operations across Asia, Europe, the Middle East and Latin America, the company has built an expansive partnership ne
Brenus Pharma Welcomes New European and Asia-Pacific Life Sciences Investors in Series A Extension20.7.2026 23:00:00 EEST | Press release
Brenus Pharma today announced an €11 million ($12.6M) extension to its Series A round, bringing total capital raised since inception to €38 million ($43.5M). This funding reflects strong execution across clinical, regulatory, and business development milestones, de-risking STC-1010 (NCT06934538): lead clinical-stage in-vivo immunotherapy for MSS mCRC, while positioning the company’s proprietary platform for multi-asset expansion. The round was supported by strong follow-on participation from existing investors, including Angelor, UI Investissement (managing FRAI), Crédit Agricole (CACE Création, CACF Capital Innovation), Noshaq, Orsa (formerly Investsud), BIO JAG, and Bpifrance (through non-dilutive funding). This round also welcomes two new international investors: Sambrinvest, strengthening the company’s European shareholder base, and Korea Omega Investment Corp, marking its first institutional investment from the Asia-Pacific region. "We couldn't be more confident in our first inves
Hollywood Chamber of Commerce Expands Into Luxury Hospitality20.7.2026 19:30:00 EEST | Press release
The Hollywood Chamber of Commerce, known for the iconic Hollywood Sign® and Hollywood Walk of Fame®, is expanding into luxury hospitality through a strategic partnership with The Scene Hotels & Resorts to launch Hollywood Hotels & Residences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260720026178/en/ The Scene Hotels & Resorts, with 40+ years of combined expertise in hospitality, travel, and brand development, will lead the brand’s development and management. The partnership will bring the Hollywood lifestyle to luxury hotels and branded residences around the world, creating immersive destinations inspired by the world's entertainment capital. "This partnership represents far more than an expansion of the Hollywood brand—it reflects our vision of Hollywood as the world's premier hub for entertainment, creativity, and commerce," said Ron Frierson, President & CEO of the Hollywood Chamber of Commerce. "By deepening our in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom